Why Immatics N.V.’s (IMTX) Stock Is Up 5.24%
As of Friday, August 28, Immatics N.V.’s IMTX share price has surged by 5.24%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna’s PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Commentary & Analysis
Why Immatics N.V.’s (IMTX) Stock Is Up 10.24%
As of Tuesday, August 25, Immatics N.V.’s IMTX share price has surged by 10.24%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Immatics N.V.’s (IMTX) Stock Is Up 8.19%
As of Friday, August 21, Immatics N.V.’s IMTX share price has surged by 8.19%, which has investors questioning if this is right time to sell.Michael Rose
What You Need to Know About Immatics N.V.'s Q3 Earnings
Immatics N.V.'s fiscal Q3 earnings report was released on Tuesday, August 18. Let's dive in to see if (IMTX) missed or beat analyst's expectations.Rosalio Madrigal
Is Immatics N.V. (IMTX) Overvalued?
We dive into why Immatics N.V. (IMTX) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Tudor Pop
Financial Summary
| Share Statistics | IMTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,306.8 | $282.4 | 48% |
|
| Shares Out (Mil) | 156.2 | 54.0 | 72% |
|
| Institutional Ownership | 92.4% | 93.1% | 61% |
|
| Float (Mil) | 70.1 | 42.2 | 54% |
|
| Beta | 1.32 | 0.94 | 76% |
|
| Avg Daily Volume (000s) | 708 | 482 | 66% |
|
| Price Change (52-week) |
67.1% | 59.9% | 86% |
|
| Growth | IMTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 8.2% | 14.1% | 51% |
|
| Net Income (5yr) | 2.2% | (10.1%) | 43% |
|
| EPS (5yr) | 18.9% | 15.9% | 66 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.3%) | (15.6%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.504) | ($2.070) | ($2.067) | |
| Month Ago EPS | ($0.490) | ($1.904) | ($1.901) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.497) | ($1.943) | ($1.892) | |
| Year/Year Chg | (4.2%) | 9.5% | (3.5%) | |
| Financials | IMTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $48 | $37 | 19% |
|
| Net Income (TTM) (Mil) | ($236) | ($43) | 6% |
|
| EPS (TTM) | ($1.823) | ($1.500) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($235) | ($31) | 3% |
|
| Net Cash Flow (TTM) (Mil) | ($25) | $2 | 24% |
|
| Long-Term Debt (Q1) (Mil) | $14 | $4 | 30% |
|
| Enterprise Value (Q1) (Mil) | $762 | $190 | 38% |
|
| Valuation | IMTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.86 | 2.84 | 63% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | IMTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (423.7%) | 66.9% | 0% |
|
| Net Margin | (495.3%) | (74.2%) | 2% |
|
| ROA | (38.6%) | (47.7%) | 14% |
|
| ROE | (47.1%) | (55.0%) | 16% |
|
| Liabilities to Assets | 17.7% | 29.8% | 11% |
|
| F-Score | 2 | 3 | 7% |
|
Passing Stock Screens
As of 9/4/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Down 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.8% |
| +/- S&P 500: | -4.7 |
